ANDA Sponsors: Update Your FDA Contacts List
Executive Summary
New policy allows more FDA staffers to answer certain questions about pending applications, rather than channeling them all through the regulatory project manager.
You may also be interested in...
GDUFA: Review Costs Continued To Climb Once Formal Review Goals Began
Generic drug reviews during the first year of formal review goals cost 70% more than during GDUFA's inaugural year.
GDUFA Stakeholder Deadline May Come After Negotiations Conclude
Generic drug user fee reauthorization talks remain on schedule and are expected to last about four months.
Generics Savings Once Again Could Help A Major US Health Care Reform Bill
A provision in the pending legislation on PBMs that would allow the US FDA to provide qualitative and quantitative information to ANDA sponsors about reference product's inactive ingredients could save hundreds of millions in spending.